Cellectis SA (CLLS)

10.04
0.31 3.20
NASDAQ : Health Technology
Prev Close 9.73
Open 9.83
Day Low/High 9.73 / 9.93
52 Wk Low/High 9.50 / 28.24
Volume 3.69K
Avg Volume 114.40K
Exchange NASDAQ
Shares Outstanding 42.45M
Market Cap 426.97M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cellectis Reports Financial Results For Second Quarter And First Six Months 2019

Cellectis Reports Financial Results For Second Quarter And First Six Months 2019

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its...

SWIFF-CAR Mechanism (Photo: Business Wire)

SWIFF-CAR Mechanism (Photo: Business Wire)

Regulatory News: This press release features multimedia. View the full release here: https://www.

Cellectis Enters Oversold Territory (CLLS)

Cellectis Enters Oversold Territory (CLLS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cellectis Reports Financial Results For First Quarter 2019

Cellectis Reports Financial Results For First Quarter 2019

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its...

Cellectis Announces Oral And Poster Presentations Of Allogeneic CAR T-Cell Programs At The 2019 ASGCT Annual Meeting

Cellectis Announces Oral And Poster Presentations Of Allogeneic CAR T-Cell Programs At The 2019 ASGCT Annual Meeting

Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announces several presentations at the upcoming 2019...

FDA Clears The IND For UCARTCS1, The First Allogeneic CAR-T To Treat Multiple Myeloma Patients

FDA Clears The IND For UCARTCS1, The First Allogeneic CAR-T To Treat Multiple Myeloma Patients

Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today that the U.

Cellectis Reports 4th Quarter And Full Year 2018 Financial Results

Cellectis Reports 4th Quarter And Full Year 2018 Financial Results

Regulatory News: Cellectis S.A.

Cellectis Enters Lease Agreement To Build Manufacturing Facility, Advancing Towards Commercialization Of Its UCART Portfolio

Cellectis Enters Lease Agreement To Build Manufacturing Facility, Advancing Towards Commercialization Of Its UCART Portfolio

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a...

Cellectis Publishes Novel Methods To Improve The Safety Of CAR T-Cell Therapy And Prevent CRS In The Journal Of Biological Chemistry

Cellectis Publishes Novel Methods To Improve The Safety Of CAR T-Cell Therapy And Prevent CRS In The Journal Of Biological Chemistry

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on allogeneic gene edited CAR T-cells (UCART), today announced the publication of a...

Cellectis Is Now Oversold (CLLS)

Cellectis Is Now Oversold (CLLS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cellectis Appoints William Monteith As Senior Vice President U.S. Manufacturing

Cellectis Appoints William Monteith As Senior Vice President U.S. Manufacturing

Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the appointment of William (Bill) Monteith to the role of...

Oversold Conditions For Cellectis (CLLS)

Oversold Conditions For Cellectis (CLLS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cellectis Reports Financial Results For 3rd Quarter And First Nine Months 2018

Cellectis Reports Financial Results For 3rd Quarter And First Nine Months 2018

Regulatory News: Cellectis S.A.

CAR-T Pioneer Dr. Stephan A. Grupp To Join Cellectis Clinical Advisory Board

CAR-T Pioneer Dr. Stephan A. Grupp To Join Cellectis Clinical Advisory Board

Regulatory News: Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A.

Calyxt Appoints CEO, Jim Blome, Former President & CEO Of Bayer CropScience LP

Calyxt Appoints CEO, Jim Blome, Former President & CEO Of Bayer CropScience LP

Regulatory News: Calyxt, Inc. (NASDAQ:CLXT) and Cellectis S.

Calyxt Appoints CEO, Jim Blome, Former President & CEO Of Bayer CropScience LP

Calyxt Appoints CEO, Jim Blome, Former President & CEO Of Bayer CropScience LP

Calyxt, Inc. (NASDAQ: CLXT) and Cellectis S.

RSI Alert: Cellectis (CLLS) Now Oversold

RSI Alert: Cellectis (CLLS) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cellectis Appoints Stefan Scherer M.D., Ph.D., As Senior Vice President Clinical Development And Deputy Chief Medical Officer

Cellectis Appoints Stefan Scherer M.D., Ph.D., As Senior Vice President Clinical Development And Deputy Chief Medical Officer

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the...

Cellectis Reports Financial Results For 2nd Quarter And First Six Months 2018

Cellectis Reports Financial Results For 2nd Quarter And First Six Months 2018

Regulatory News: Cellectis S.A.

Cellectis S.A. Reports Results From Annual General Meeting Held On June 26, 2018

Cellectis S.A. Reports Results From Annual General Meeting Held On June 26, 2018

Regulatory News: Cellectis S.A.

Cellectis Publishes Novel Methods To Improve The Clinical Use Of Chimeric Antigen Receptor T-Cell Therapy In Scientific Reports

Cellectis Publishes Novel Methods To Improve The Clinical Use Of Chimeric Antigen Receptor T-Cell Therapy In Scientific Reports

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced the publication of a study in Scientific...

FDA Grants Cellectis IND Approval For UCART22 In B-ALL

FDA Grants Cellectis IND Approval For UCART22 In B-ALL

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that the...

INSERTING And REPLACING: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

INSERTING And REPLACING: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

Regulatory News: This replaces the announcement made at 22:30 CEST on 22 May 2018 due to the following addendum: More information has been added to the first bullet point after the second paragraph Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a...

Cellectis: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

Cellectis: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the...

Calyxt Announces Launch Of Proposed Follow-On Offering

Calyxt Announces Launch Of Proposed Follow-On Offering

Regulatory News: Cellectis S.A.

Cellectis To Present Data At The 2018 ASGCT Annual Meeting

Cellectis To Present Data At The 2018 ASGCT Annual Meeting

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that...

TheStreet Quant Rating: D (Sell)